Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168714 · ClinicalTrials.gov registry record
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 329
- Enrollment target
NCT00168714: Completed study, sponsored by Biogen.
NCT00168714 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 329 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00168714 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 329 participants
- Enrollment target
Study Summary
The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was unknown prospectively and to prospectively record and analyze pregnancy outcomes in an exploratory fashion of women with MS who stopped therapy, but who may have been exposed to Avonex with approximately 1 week of conception or during the first trimester of pregnancy.
Interventions
- DRUG BG9418 (interferon beta-1a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2004-02 |
| Est. Completion | 2011-09 |
What the finished NCT00168714 record still lists
NCT00168714 is an observational study that tracks outcomes without assigning an intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which BG9418 (interferon beta-1a) is the first listed.
NCT00168714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00168714 about?
NCT00168714 is a clinical study titled "Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)". The primary objectives of the study were to prospectively record and analyze birth defects and spontaneous fetal losses in women with multiple sclerosis (MS) exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy, where the outcome of the pregnancy was...
What is the current status of trial NCT00168714?
This trial is currently completed. The enrollment target is 329 participants. The study started on 2004-02. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00168714?
The interventions under investigation include: BG9418 (interferon beta-1a) (DRUG).
Who is sponsoring clinical trial NCT00168714?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia